The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and drug resistance. Based on their morphology and phenotype, MDSC are commonly subdivided into polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC), both characterized by their immunosuppressive function. The phenotype, function and prognostic value of MDSC in hematological cancers has been intensively studied; however, the therapeutic targeting of this cell population remains challenging and needs further investigation. In this review, we will summarize the prognostic value of MDSC and the different attempts to target MDSC (or subtypes of MDSC) in hematological cancers. We will discuss the benefits, challenges and opportunities of using MDSC-targeting approaches, aiming to enhance anti-tumor immune responses of currently used cellular and non-cellular immunotherapies.
Bibliographical noteFunding Information:
This work was supported by Fonds voor Wetenschappelijk Onderzoek (FWO), Wetenschappelijk Fonds Willy Gepts (WFWG), and Strategic Research Programme (SRP48). KDV is a postdoctoral fellow of FWO (12I0921N).
Copyright © 2022 Fan, De Beule, Maes, De Bruyne, Menu, Vanderkerken, Maes, Breckpot and De Veirman.
Copyright 2022 Elsevier B.V., All rights reserved.
- hematological malignancies